{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:40:11Z","timestamp":1785526811050,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Special Funds of WU JIEPING medical foundation for clinical research project","award":["320.6750.2022-20-40"],"award-info":[{"award-number":["320.6750.2022-20-40"]}]},{"name":"Special Research Fund for the Central High-level Hospitals of Peking Union Medical College Hospital","award":["2022-PUMCH-B-058"],"award-info":[{"award-number":["2022-PUMCH-B-058"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01155-7","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:43:51Z","timestamp":1780033431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective study of the efficacy and safety of rituximab biosimilar for the treatment of membranous nephropathy"],"prefix":"10.1186","volume":"27","author":[{"given":"Yu-zhen","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-li","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1155_CR1","doi-asserted-by":"publisher","unstructured":"Seitz-Polski B. Dahan, High-dose rituximab and early remission in PLA2R1-Related membranous nephropathy. Clin J Am Soc Nephrol. 2019(8): 1\u201310. https:\/\/doi.org\/10.2215\/cjn.11791018","DOI":"10.2215\/cjn.11791018"},{"key":"1155_CR2","doi-asserted-by":"publisher","unstructured":"Gauckler P, Shin JI, Alberici F, et al. Rituximab in membranous nephropathy. Kidney Int Rep. 2021;6881\u201393. https:\/\/doi.org\/10.1016\/j.ekir.2020.12.035.","DOI":"10.1016\/j.ekir.2020.12.035"},{"key":"1155_CR3","doi-asserted-by":"publisher","unstructured":"Brad H, Rovin SG, Adler J, Barratt, International K, et al. Volume 100, Issue 4, 2021, Pages S1-S276, ISSN 0085\u20132538, https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"1155_CR4","unstructured":"National Medical Products Administration (NMPA). Center for Drug Evaluation. Guidelines for clinical trials of rituximab biosimilars [EB\/OL]. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20200720171501333.html.2020-7-20\/2023-1-14."},{"key":"1155_CR5","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products[M]. London: committee for medicinal products for human Use (CHMP). 23 Oct 2014: 1\u20137."},{"issue":"3","key":"1155_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.21147\/j.issn.1000-9604.2021.03.11","volume":"33","author":"Y Shi","year":"2021","unstructured":"Shi Y, Zhang Q, Han X, et al. Phase 1 Studies Comparing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HLX01 (a Rituximab Biosimilar) to Reference Rituximab in Chinese Patients with CD20-positive B-cell Lymphoma. Chin J Cancer Res. 2021;33(3):405\u201316. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.03.11.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"1155_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-020-00871-9","volume":"13","author":"Y Shi","year":"2020","unstructured":"Shi Y, Song Y, Qin Y, et al. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13(1):38. https:\/\/doi.org\/10.1186\/s13045-020-00871-9.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1155_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13075-022-02821-x","volume":"24","author":"X Zeng","year":"2022","unstructured":"Zeng X, Liu J, Liu X, et al. HLX01-RA03 Investigators. Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study. Arthritis Res Ther. 2022;24(1):136. https:\/\/doi.org\/10.1186\/s13075-022-02821-x.","journal-title":"Arthritis Res Ther"},{"key":"1155_CR9","unstructured":"NMPA. Technical guidelines for the development and evaluation of Biosimilars (Trial)[EB\/OL]. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20150228155701114.html. 2015-2-28\/2023-1-14."},{"key":"1155_CR10","unstructured":"EMA. Guideline on similar biological medicinal products [EB\/OL]. https:\/\/www.fdanews.com\/ext\/resources\/files\/10-14\/10-14-EMA-Biosimilars.pdf?1520782705. 2014-20-23\/2023-01-14."},{"key":"1155_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.ki.5002628","volume":"73","author":"FC Fervenza","year":"2008","unstructured":"Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008;73:117\u201325. https:\/\/doi.org\/10.1038\/sj.ki.5002628.","journal-title":"Kidney Int"},{"key":"1155_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ekir.2016.05.002","volume":"1","author":"M Waldman","year":"2016","unstructured":"Waldman M, Beck LH Jr, Braun M, et al. Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and rituximab. Kidney Int Rep. 2016;1:73\u201384. https:\/\/doi.org\/10.1016\/j.ekir.2016.05.002.","journal-title":"Kidney Int Rep"},{"key":"1155_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381:36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1814427.","journal-title":"N Engl J Med"},{"issue":"3","key":"1155_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000430849","volume":"130","author":"F Fervenza","year":"2015","unstructured":"Fervenza F, Canetta P, et al. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron. 2015;130(3):159\u201368. https:\/\/doi.org\/10.1159\/000430849.","journal-title":"Nephron"},{"key":"1155_CR15","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, Logt A-E et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy [e-pub ahead of print]. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2020.10.014, Accessed March 12, 2021.","DOI":"10.1016\/j.kint.2020.10.014"},{"issue":"8","key":"1155_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3969\/j.issn.1003-3734.2020.18.020","volume":"30","author":"ZHANG Chun-yan","year":"2021","unstructured":"Chun-yan ZHANG, Li-qiu XING, Lei ZHONG, et al. Analysis of rituximab-induced serious adverse drug reaction between 2003\u20132019 in Beijing. Chin J New Drugs. 2021;30(8):765\u20138. https:\/\/doi.org\/10.3969\/j.issn.1003-3734.2020.18.020.","journal-title":"Chin J New Drugs"},{"issue":"3","key":"1155_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3760\/cma.j.cn112138-20210927-00660","volume":"61","author":"Nephrology Expert Panel of the Peking University Health Science Center","year":"2022","unstructured":"Nephrology Expert Panel of the Peking University Health Science Center. Expert consensus on the application of Rituximab in the treatment of membranous nephropathy. Chin J Intern Med. 2022;61(3):282\u201390. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20210927-00660.","journal-title":"Chin J Intern Med"},{"key":"1155_CR18","doi-asserted-by":"publisher","unstructured":"Jang M, Simoens S, Kwon T. Budget Impact analysis of the introduction of rituximab and trastuzumab intravenous biosimilars to EU-5 markets. Springer Int Publishing.2021(1). https:\/\/doi.org\/10.1007\/S40259-020-00461-8.","DOI":"10.1007\/S40259-020-00461-8"},{"key":"1155_CR19","doi-asserted-by":"publisher","unstructured":"Jacopo Giuliani, Andrea Bonetti. The Economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 2019;393971\u20133. https:\/\/doi.org\/10.21873\/anticanres.13552.","DOI":"10.21873\/anticanres.13552"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01155-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:03:58Z","timestamp":1785521038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01155-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01155-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4586149\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"15 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Peking Union Medical College Hospital Ethics Committee [reference number I-22PJ401]. As this study is a retrospective and non-interventive study, also no identifiable personal data were disclosed, informed consent to participate has been granted an exemption from ethical approval.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"101"}}